Crisaborole Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Crisaborole Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
123
Registered trials
39
Result records
28
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Crisaborole can convert its Small molecule drug profile and PDE4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Crisaborole (query alias: crisaborole) |
|---|---|
| Modality / target | Small molecule drug; PDE4; PDE4 inhibitors |
| Highest global status | Approved |
| Originator | Anacor Pharmaceuticals LLC |
| Active developers | Anacor Pharmaceuticals LLC, Pfizer Investment Co. Ltd., Pfizer Australia Pty Ltd. |
The MCP disease footprint includes Dermatitis, Atopic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600125285 | Early Phase 1 | Not yet recruiting | 80 | Vitiligo Area Scoring Index (VASI) |
| ChiCTR2600123562 | Not Applicable | Not yet recruiting | 65 | Improvement rate of PPPASI score from baseline at week 8 |
| NCT07537751 | Not Applicable | Completed | 40 | Percentage improvement in objective SCORAD from baseline to Week 6 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Quantification of Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis on Crisaborole Ointment, 2%
Phase 4; n=72; evaluation: not stated. Reported fields: -; Number of Children's Nighttime Scratching Episodes(Mean) = 93.04 scratch count per night (Standard Deviation, 70.35); -
Proof of Concept Investigation of the Steroid-reducing Effects of Crisaborole in Children
Phase 4; n=24; evaluation: not stated. Reported fields: Steroid Usage Quantity(Mean) = 10.78 grams (Standard Deviation, 20.77); -; Steroid Usage Quantity(Mean) = 8.22 grams (Standard Deviation, 10.39)
Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
Phase 3; n=237; evaluation: Positive. Reported fields: ISGA(improvement) = 33.4 % (95%CI, 22.5 - 44.2); ISGA(improvement) = 43.2 % (95%CI, 35.4 - 51.1)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Crisaborole addresses Dermatitis, Atopic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 28 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PDE4 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-18 | cAMPfield to develop and commercialize Newsoara' prifemilast for IBD worldwide excluding Greater China | Phase 3 | Financial terms not disclosed |
| 2026-01-26 | Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa | Approved | Financial terms not disclosed |
| 2026-01-09 | AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD) Share | Phase 2 | US$40.0M upfront; US$955.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Transdermal administration of PDE4 inhibitors for reduction in adverse events”. The milestone feed surfaced a patent-application signal described as “Synthesis method of crisaborole”. The milestone feed surfaced a patent-application signal described as “Synthesis method of crisaborole”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
